CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


DAS181Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (11)


Name (Synonyms) Correlation
drug700 DAS181 OL Wiki 0.41
drug582 Clinical data Wiki 0.41
drug699 DAS181 COVID-19 Wiki 0.41
drug652 Convalescent Plasma Transfusion Wiki 0.29
drug290 BI 894999 Wiki 0.24
drug1219 Interferon Beta-1A Wiki 0.20
drug923 Favipiravir Wiki 0.20
drug1860 Placebos Wiki 0.10
drug1270 Ivermectin Wiki 0.10
drug1822 Placebo Wiki 0.07
drug1086 Hydroxychloroquine Wiki 0.04

Correlated MeSH Terms (11)


Name (Synonyms) Correlation
D018184 Paramyxoviridae Infections NIH 0.24
D002277 Carcinoma NIH 0.18
D002318 Cardiovascular Diseases NIH 0.17
D000066553 Problem Behavior NIH 0.15
D002908 Chronic Disease NIH 0.13
D007251 Influenza, Human NIH 0.12
D006973 Hypertension NIH 0.11
D001523 Mental Disorders NIH 0.09
D012141 Respiratory Tract Infections NIH 0.09
D003141 Communicable Diseases NIH 0.07
D007239 Infection NIH 0.05

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0030731 Carcinoma HPO 0.18
HP:0001626 Abnormality of the cardiovascular system HPO 0.17
HP:0000708 Behavioral abnormality HPO 0.15
HP:0000822 Hypertension HPO 0.11
HP:0011947 Respiratory tract infection HPO 0.09

There are 6 clinical trials

Clinical Trials


1 A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

NCT03808922 Lower Respiratory Tract Infection Parainfluenza Immunocompromised COVID-19 Drug: DAS181 Drug: Placebo Drug: DAS181 COVID-19 Drug: DAS181 OL
MeSH:Infection Communicable Diseases Respiratory Tract Infections Paramyxoviridae Infections
HPO:Respiratory tract infection

Primary Outcomes

Description: Removal of all oxygen support (with stable SpO2)

Measure: Percent of subjects who Return to Room Air (RTRA) (main study)

Time: by Day 28

Measure: Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)

Time: Day 14

Secondary Outcomes

Measure: All-cause mortality rate (main study)

Time: at Day 28

Measure: Percent of subjects who Return to Room Air (RTRA) (main study)

Time: by Day 21

Measure: Time (in days) to RTRA (main study)

Time: Days 10, 14, 21, 28

Measure: Percent of subjects who achieve clinical stability (main study)

Time: by Day 28

Measure: Percent of subjects discharged (without mortality and hospice) (main study)

Time: by Days 14, 21, 28 and 35

Measure: Time (in days) to first hospital discharge (without hospice) (main study)

Time: through Day 35

Measure: Total number of inpatient days (main study)

Time: up to Day 35

Measure: Baseline SAD-RV infection-related mortality rate (main study)

Time: at Day 28

Measure: Baseline SAD-RV infection-related mortality rate (main study)

Time: at Day 35

Measure: All-cause mortality rate (main study)

Time: at Day 35

Measure: Change in pulmonary function (FEV1% predicted) (main study)

Time: Day 1, Day 7, Day 14, Day 28

Measure: Time to improved COVID19 clinical status (Sub-study)

Time: Day 5, Day 10, Day 21, Day 28

Measure: Time to RTRA

Time: Day 10, Day 14, Day 21, Day 28

Measure: Time to Clinical stability

Time: Day 14, Day 21, Day 28

Measure: Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable

Time: Day 5, Day 10, Day 14, Day 21, Day 28

Measure: Time to Clinical deterioration

Time: Day 5, Day 10, Day 14, Day 21, Day 28

Measure: Time to Discharge from hospital (without readmission before Day 28).

Time: Day 14, Day 21, Day 28

Measure: Time to Death (all causes)

Time: Day 14, Day 21, Day 28

2 A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

NCT04298060 Influenza Infection SAD-RV Infection and COVID-19 Drug: DAS181 Drug: Placebo
MeSH:Infection Communicable Diseases Influenza, Human

Primary Outcomes

Description: Percent of subjects who have returned to room air

Measure: Percent of subjects who have returned to room air

Time: 7 days

Description: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1

Measure: Percent change of subjects return to baseline oxygen requirement

Time: 7 days

3 DAS181 for Severe COVID-19: Compassionate Use

The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.

NCT04324489 COVID-19 Drug: DAS181

Primary Outcomes

Description: Percent of subjects with improved clinical status

Measure: Improved clinical status

Time: Day 14

Description: Percent of subjects return to room air

Measure: Return to room air

Time: Day 14

Secondary Outcomes

Description: time to SARS-CoV-2 RNA in the respiratory specimens being undetectable

Measure: SARS-CoV-2 RNA

Time: 28 days

Description: Percent of patients discharge from hospital

Measure: Discharge

Time: Days 14, 21, 28

Description: All-cause mortality rate

Measure: Death

Time: Day 14, 21, 28

4 DAS181 for COVID-19: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.

NCT04354389 COVID-19 Drug: DAS181 Drug: Placebo Drug: DAS181

Primary Outcomes

Measure: Percent of subjects return to room air (RTRA)

Time: Day 14

Secondary Outcomes

Description: Percent of subjects who reach level 1 of COVID-19 Clinical Classification (discharged or return to normal activity)

Measure: Percent of subjects who have recovered

Time: Day 5, 10, 14, 21, 28

Description: time to Improved COVID-19 Clinical Classification 1 to 6 (where higher score means worse outcome)

Measure: Improved COVID-19 Clinical Classification

Time: Day 28

Description: Percent of subjects RTRA

Measure: Return To Room Air (RTRA)

Time: Day 10, 21, 28

Measure: Percent of subjects who achieve clinical stability

Time: Day 28

Description: Time to

Measure: SARS-CoV-2 RNA undetectable

Time: Day 28

Description: Time to

Measure: Clinical Deterioration

Time: Day 28

Description: Percent of subjects discharge

Measure: Percent of subjects discharged

Time: Day 14, 21, 28

Description: Time to

Measure: Death (all cause)

Time: Day 28

5 DAS181 for COVID-19: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.

NCT04354389 COVID-19 Drug: DAS181 Drug: Placebo Drug: DAS181

Primary Outcomes

Measure: Percent of subjects return to room air (RTRA)

Time: Day 14

Secondary Outcomes

Description: Percent of subjects who reach level 1 of COVID-19 Clinical Classification (discharged or return to normal activity)

Measure: Percent of subjects who have recovered

Time: Day 5, 10, 14, 21, 28

Description: time to Improved COVID-19 Clinical Classification 1 to 6 (where higher score means worse outcome)

Measure: Improved COVID-19 Clinical Classification

Time: Day 28

Description: Percent of subjects RTRA

Measure: Return To Room Air (RTRA)

Time: Day 10, 21, 28

Measure: Percent of subjects who achieve clinical stability

Time: Day 28

Description: Time to

Measure: SARS-CoV-2 RNA undetectable

Time: Day 28

Description: Time to

Measure: Clinical Deterioration

Time: Day 28

Description: Percent of subjects discharge

Measure: Percent of subjects discharged

Time: Day 14, 21, 28

Description: Time to

Measure: Death (all cause)

Time: Day 28

6 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study

On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

NCT04460547 COVID-19 Drug: Convalescent Plasma Transfusion Drug: Hydroxychloroquine Drug: DAS181 Drug: Ivermectin Drug: Interferon Beta-1A

Primary Outcomes

Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.

Measure: Geographical distribution of the interventional studies after 11th of March 2020.

Time: 15th of August 2020

Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.

Measure: Geographical distribution of the Observational studies after 11th of March 2020.

Time: 15th of August 2020

Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.

Measure: Monthly Research study completion rate as per geographic distribution of the Research.

Time: 15th of August 2020

Secondary Outcomes

Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020

Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.

Time: 15th of August 2020


Related HPO nodes (Using clinical trials)


HP:0011947: Respiratory tract infection
Genes 664
CCDC39 KMT2D RSPH1 DOCK8 NKX2-1 CCNO SPAG1 LIMK1 MPLKIP RAG1 DSG1 BIRC3 ELP1 TSC2 IL17F BLNK BACH2 SGSH IKBKB CD79A AFF4 ARID1B TNFRSF13C CD19 DNAH1 MYO5A AICDA NOTCH3 ELN LAMTOR2 NADK2 CTLA4 DPM2 PWAR1 GATA6 SFTPC FOXN1 MESP2 ELANE CD81 PNP MED25 ZAP70 RAG2 WRAP53 DNAAF1 STAT3 ATM LTBP3 CLCA4 DNAH9 BTK RSPH3 TERT TYK2 LRBA RSPH4A SOX11 RYR1 TNNT2 SMARCD2 GAS8 SLC5A7 KIF1A ROR2 NCF4 COLQ TNFRSF13B HLA-B CCDC65 COL11A2 ORC6 DCLRE1C CTLA4 CACNA1C GBA RNF113A ICOS SETBP1 CYBC1 MGP VPS33A COL13A1 MYSM1 DNAAF4 FLI1 MECP2 MAN2B1 HLA-DQA1 SCNN1A GLB1 IL21R CSF2RB SELENON INPPL1 CD3G ACADVL COL6A3 NSMCE3 AGA CCDC65 HGSNAT AP3D1 NFIX EXOSC9 RAG2 KIAA0586 FCGR2A ABCA12 NFKB2 TFRC NDN MAPK1 LAMA2 NCF4 ARSB LYST RAG1 TPP2 TGFB1 INPPL1 RAG2 TNFSF11 XIAP UNG SCNN1A DNAAF6 SCN10A IL2RG CCDC103 CLCN7 IGHM GNPTAB DNAAF4 CXCR4 PLEC HLA-DPB1 OCRL RFXAP SCN11A CFB TNNI3 TINF2 DCLRE1C MAGEL2 TAF1 SCNN1B CARD11 USB1 GTF2IRD1 CCDC103 SNORD115-1 IL2RG HLA-DQB1 TBC1D23 DLL3 RFXANK MYO9A SCNN1G CD79A ICOS RFC2 TAP1 CD3D FOXJ1 AGRN PIK3R1 WIPF1 RSPH4A IL2RG ACTA1 SRP54 RPGR SNAP25 TSC1 CORO1A IRF8 NCF2 GAS8 ZNHIT3 FOXP1 EP300 JAGN1 ZBTB24 TGFB1 TNFRSF13B CD3E DNAL1 EXTL3 NCF1 SNRPN B2M CLIP2 SCNN1G SFTPC LRRC56 WAS RMRP FUCA1 RSPH9 PEX13 GATA4 CFI ERCC3 FOXP1 ITGA3 PCGF2 TNFRSF13C ATP6V0A2 DNMT3B LEP BCR ZBTB24 NELFA RNF125 NECTIN1 EPM2A TGM1 CCDC40 JAK3 NEK10 MYPN RAC1 CREBBP DNAI2 PLG DDR2 UGP2 NME8 COL6A1 SLC25A1 ECM1 CD3E NFKBIA IGLL1 CHRM3 PRTN3 COG6 CD8A STX1A DNAI1 CYBB IDUA GSN EPG5 TCIRG1 DNAJB13 EDARADD TERT CR2 SOX4 NSD2 GAA TARS1 LEPR ELP1 ALMS1 IL2RB SULT2B1 RAG2 SLC25A24 SMPD1 WDR19 CHAMP1 DNAJB13 FOXP3 RNU4ATAC PLP1 ARID1A CFAP410 BTK TCTN3 RFXANK MYH3 FCN3 SMARCE1 ALPL SLC18A3 IL17RA NR2F2 NKX2-1 SCNN1G CCBE1 SLC52A3 PWRN1 DCLRE1C RYR1 AGA CIITA CR2 LRRC6 PIGN CFAP298 DNAAF5 CCNO BLM CFTR NCF1 CR2 IL2RA LCK UMPS USP9X CD3D ARID2 RUNX2 SLC35C1 TIMM8A NGLY1 NFKB2 CCDC114 TPM3 SCNN1B ADA LRRC56 PEPD IPW KATNIP LYST GRHL3 CCDC151 NBN SYT2 SPAG1 PRKCD LAMB2 CTC1 PMM2 DNAAF3 FLNC DNAAF1 POLR3A LIPN STAT1 TECPR2 SCNN1B RAG1 SDR9C7 ASAH1 DNAAF6 CRELD1 MYSM1 OSTM1 GBA CYBA RNU4ATAC COL13A1 VAMP1 MGP SMARCC2 MCIDAS G6PC3 IL17RC PSAP KAT6B PIK3R1 CD81 SLC1A4 NOP10 NGLY1 MANBA SHROOM4 ALB SMARCD1 SCNN1A CD19 ALMS1 GUSB TTC25 SMN1 RIPK1 UNC119 IGHM CD79B CFAP221 SAMD9 CYP4F22 GTF2H5 GLI3 IGLL1 SLC29A3 RPGR SCNN1B STK36 PLOD1 DNAAF5 GMNN RAG1 GNS COL11A2 OFD1 TNFRSF11A MALT1 NFE2L2 CD19 DCTN4 COG4 SCNN1A CD40LG NME8 SELENON ADNP CFTR NPAP1 CFTR DOCK8 CFAP298 SMPD1 RAG1 P4HTM MAN2B1 SLC26A2 CFAP300 RAB3GAP2 ALG12 JAK3 GTF2E2 IL21 BCL10 NRAS PRKDC TNFRSF13C SH3KBP1 ZNF341 NXN RSPH9 RFXAP SPEF2 MSN LIG4 MCM4 TBCE GALNS SLC12A6 NIPBL STAT3 ZMYND10 IL7R NAGLU HELLS CTSC NIPAL4 RASGRP1 SMARCB1 SP110 LETM1 RSPH1 CCDC39 ARMC4 LAMTOR2 TNFRSF1A IKZF1 IKBKB DNAI2 MBTPS2 FBLN5 ACP5 PTPRC NFKB2 ZAP70 TPM2 TCIRG1 NEK10 ARMC4 MS4A1 MTHFD1 CARMIL2 UBE2A EGFR RYR1 ADA DNAI1 PLCG2 PTPN22 DNMT3B BAZ1B TAPBP RTEL1 ABCA12 SNX10 CSF2RA MESP2 SMARCA4 AK2 DNAH11 KCNJ6 HACD1 DCLRE1C SAMD9L PNP ITGA7 ALOXE3 HLA-DPA1 HERC2 SLC46A1 LRRC8A IER3IP1 TSC2 TGFB1 TRAF3IP2 HPS6 ADA ICOS FLNA TRIP4 FMO3 DPF2 GFI1 ARID1B IRAK4 MKRN3-AS1 VPS33A DNAAF2 NOTCH2 SFTPA2 PCNT CRLF1 ELANE DNAH5 NFKB1 PANK2 GBA GAS2L2 GTF2I CD247 STAT1 RAG2 CCDC151 WAS EPG5 SLC25A22 DYNC2I2 XIAP SLC35A1 GNPTAB TK2 MS4A1 IFNGR1 LEPR CRKL CIITA NPM1 ZMYND10 COL6A2 ATM RNF168 GAS2L2 CDCA7 PRPS1 EHMT1 ERF NHLRC1 TBX6 MUC5B VPS13A RFX5 ASAH1 DNAH5 HYDIN FCGR3A RELB ADAMTS3 SCN9A TTC12 SH2D1A PTPN22 LEP CYBA PGM3 IL17RA MKRN3 NOS1 AFF4 ERCC2 SDCCAG8 IFIH1 CD79B TBC1D24 CHD7 GATA2 POLE LRRC6 TERC TNFRSF13B TAP2 CFTR OFD1 WASHC5 RANBP2 IL7R MYL2 TRAIP CCDC22 IGH CCDC40 IL2RG SNORD116-1 ALOX12B NFKB1 STING1 NCF2 TRPS1 SGCG PARN CHAT TSC1 TBL2 CTCF ACTA1 CACNA1B UBB PIK3CD PEPD DNAAF3 TTC25 CARD11 DNAAF2 CXCR4 MASP2 IL6ST TBC1D24 DRC1 TBCD TCF3 CYBB PIK3R1 SMN1 RSPH3 COG4 TNFSF12 CSPP1 KIF20A USP9X NHP2 HYDIN NBN PYROXD1 CASP8 IL7R SCNN1G CCDC114 TNFSF12 BTK SPINK5 BLNK CD55 IDUA USB1 SIK1 FLNA CLEC7A MAP3K20 KPTN RFX5 FAT4 DKC1 KDM6A IDUA POLA1 TRIP11 PGM3 GUSB DNAH11 KRAS
Protein Mutations 1
H275Y
SNP 0